MORATORIUM (JUDICIAL REORGANISATION)

DEVAPHAR

Export PDF

Financial year 2024 · closed on 31/12/2024

Net result

49,1 k €

-27.7% YoY

Gross margin

262,3 k €

-16.9% YoY

Equity

654,2 k €

+8.1% YoY

Company — Moratorium (judicial reorganisation).

Strike-off: 29 mai 2026

What does DEVAPHAR do?

DEVAPHAR is a Private limited company incorporated in 2001. Its main activity is: Dispensing chemist in specialised stores. Its registered office is in Bruxelles.

Legal situation

● Moratorium (judicial reorganisation)

BCE/KBO no. / VAT

BE 0474.481.042

Incorporation

03/04/2001

Legal form

Private limited company

Registered office

Avenue Louise 200 box 8
1050 Bruxelles · BruxellesSee on map

Contributed capital

6 200,00 €

Latest accounts

31/12/2024

Activities (NACE)

47730Dispensing chemist in specialised stores· main 47730Dispensing chemist in specialised stores 52310Warehousing and support activities for transportation

Joint committees (1)

Signals

ProfitableSolid equityGood liquidityPositive cashflowPositive EBITDAHealthy social debts

View the BCE/KBO Public Search record →

Health score

Available with a Rovalta subscriptionTry for 7 days

Recommended credit limit

✦ Verdict · Analyst summary

Financials

Trend over 19 financial years

	2024		2023		2022		2021		2020		2019		2018		2017		2016		2015		2014		2013		2012		2011		2010		2009		2008		2007		2006
Income statement
Gross margin	262,3 k €	-16.9%	315,7 k €	-17.9%	384,7 k €	+76.7%	217,7 k €	+23.8%	175,8 k €	+173%	64,4 k €	-12.7%	73,8 k €	-6.4%	78,8 k €	-14.7%	92,5 k €	-7.9%	100,4 k €	+12.5%	89,3 k €	+83.2%	48,8 k €	-41.0%	82,6 k €	-13.9%	96,0 k €	-14.8%	112,7 k €	+0.6%	112,0 k €	+12.8%	99,3 k €	+80.4%	55,0 k €	-26.7%	75,1 k €
EBITDA	106,7 k €	-33.9%	161,3 k €	-40.3%	270,2 k €	+51.4%	178,5 k €	+23.2%	144,9 k €	+144%	59,3 k €	-16.3%	70,9 k €	-8.3%	77,3 k €	-14.5%	90,4 k €	-8.2%	98,5 k €	+12.7%	87,3 k €	+86.6%	46,8 k €	+7.6%	43,5 k €	-49.9%	86,8 k €	-21.4%	110,5 k €	+0.7%	109,7 k €	+14.4%	95,9 k €	+85.6%	51,7 k €	-29.7%	73,5 k €
Operating result	80,0 k €	-42.4%	139,0 k €	-41.2%	236,2 k €	+58.9%	148,6 k €	+17.5%	126,4 k €	+215%	40,1 k €	-21.0%	50,8 k €	-11.6%	57,4 k €	-16.1%	68,4 k €	+2.3%	66,9 k €	+18.5%	56,5 k €	+81.7%	31,1 k €	+7.7%	28,9 k €	-54.6%	63,5 k €	-12.9%	72,9 k €	+0.4%	72,7 k €	+21.8%	59,7 k €	+281%	15,7 k €	-60.5%	39,7 k €
Net result	49,1 k €	-27.7%	67,9 k €	-57.3%	158,8 k €	+73.8%	91,4 k €	+7.5%	85,0 k €	+304%	21,0 k €	-33.8%	31,8 k €	-9.7%	35,2 k €	-19.0%	43,5 k €	-3.3%	45,0 k €	+58.1%	28,4 k €	+26.5%	22,5 k €	+7.7%	20,9 k €	-35.5%	32,4 k €	-34.9%	49,8 k €	-2.6%	51,1 k €	+37.5%	37,2 k €	+394%	7,5 k €	-53.9%	16,3 k €
Balance sheet
Equity	654,2 k €	+8.1%	605,1 k €	+12.6%	537,2 k €	+42.0%	378,4 k €	+31.8%	287,0 k €	+42.1%	202,0 k €	+11.6%	181,0 k €	+21.3%	149,2 k €	+11.3%	134,0 k €	+21.2%	110,5 k €	+23.4%	89,6 k €	-6.8%	96,1 k €	-15.4%	113,6 k €	-14.4%	132,8 k €	-4.7%	139,4 k €	+7.5%	129,6 k €	+9.4%	118,5 k €	+1.0%	117,3 k €	+6.8%	109,8 k €
Total assets	1,6 M €	-8.0%	1,8 M €	+56.6%	1,1 M €	+56.6%	721,1 k €	+10.8%	650,8 k €	+53.6%	423,6 k €	+33.4%	317,7 k €	-4.5%	332,6 k €	-2.9%	342,6 k €	+6.8%	320,9 k €	-8.6%	351,3 k €	+88.9%	186,0 k €	-8.3%	202,8 k €	-12.9%	232,9 k €	-20.1%	291,5 k €	-17.4%	353,0 k €	-3.7%	366,4 k €	-2.4%	375,5 k €	-1.6%	381,8 k €
Cash	6,3 k €	+12.5%	5,6 k €	-86.7%	42,0 k €	-20.1%	52,6 k €	-62.8%	141,3 k €	+326%	33,2 k €	-51.8%	68,8 k €	+98.7%	34,6 k €	+11.9%	30,9 k €	+36.5%	22,7 k €	+492%	3,8 k €	-52.0%	8,0 k €	-6.4%	8,5 k €	-21.9%	10,9 k €	+9.1%	10,0 k €	+35.0%	7,4 k €	-25.3%	9,9 k €	-68.3%	31,3 k €	-24.5%	41,4 k €
Debts	972,3 k €	-16.4%	1,2 M €	+96.4%	591,7 k €	+72.7%	342,7 k €	-5.8%	363,8 k €	+64.2%	221,6 k €	+63.6%	135,5 k €	-25.6%	182,2 k €	-12.2%	207,4 k €	-0.8%	209,2 k €	-19.7%	260,5 k €	+190%	89,8 k €	+0.8%	89,1 k €	-11.0%	100,1 k €	-34.2%	152,1 k €	-31.7%	222,6 k €	-10.2%	247,9 k €	-4.0%	258,2 k €	-5.1%	272,0 k €
Other
Workforce	–		–		–		–		–		–		–		–		–		–		–		–		0,7 ETP	+250%	0,2 ETP		–		–		–		–		–

Governance

Board of directors

Seen on filing of 31/12/2024 · 1 active · 6 ended

Active mandates

CIEL PHARMA

Administrateur · since 08 novembre 2024 · 0690.987.220

Represented by Ilias Atghaninti

Active

Ended mandates

CIEL PHARMA

Director · since 02 janvier 2019 · 0690.987.220

Represented by ILIAS ATGHANINTI

Ended

MICHELINE DEMARBAIX

Managing director · since 01 juillet 2015

Ended

PAUL MARIE VANDERBORCHT

Managing director · since 01 avril 2001

Ended

CIEL PHARMA

Manager · 0690.987.220

Represented by LLIAS ATGHANINTI

Ended

At this address

Other companies at this address

Company	CBE no.
ABX Dynamics● Active	1018.716.665
ACB EPURE ARCHITECTS● Active	0816.999.821
A.N. Cleaning Partners● Active	1029.130.705
Association des copropriétaires de l'immeuble à Bruxelles , avenue Louise 198-204 et rue Lens 1-9● Active	0837.743.666
Brussels Business Institute of Higher Education● Liquidation	0883.831.336
BTC LEGAL● Active	1009.239.369
Casa● Liquidation	0415.343.607
CECILIA PATAUT● Active	1016.674.618
CHRISTOPHE GOOSSENS & ASSOCIES● Liquidation	0476.089.361
CIEL PHARMA● Active	0690.987.220
CONSEIL ECONOMIQUE ET COMMERCIAL BELGIQUE-CHINE-CHAMBRE DE COMMERCE BELGIQUE-CHINE● Active	0434.434.294
CORPOCONSULT● Active	0838.344.868
D2Cadre Consult● Active	1026.707.782
FEDERATION DES AGENCES IMMOBILIERES SOCIALES DE LA REGION BRUXELLOISE-FEDERATIE VAN DE SOCIALE VERHUURKANTOREN VAN HET BRUSSELSE GEWEST● Active	0866.494.862
Fédération des Opérateurs Culturels des Arts du Conte et de l'Oralité● Active	0678.933.088
FISCAMIN● Active	1029.468.522
F.S BUSINESS MANAGEMENT● Active	0650.607.209
GOLDMANN ESTATES.EU● Active	0462.551.131
GOLDMANN.EU● Judicial reorganisation	0752.859.164
GOOD WAY MANAGEMENT● Active	0649.922.962

Annual accounts

Full financial information

	2024	2023	2022	2021	2020	2019
Type of account	Micro model	Micro model	Micro model	Abridged model	Micro model	Micro model
Start of the financial year	01/01/2024	01/01/2023	01/01/2022	01/01/2021	01/01/2020	01/01/2019
Closing of the financial year	31/12/2024	31/12/2023	31/12/2022	31/12/2021	31/12/2020	31/12/2019
Length of the financial year	12 months	12 months	12 months	12 months	12 months	12 months
Filing date	14/11/2025	30/07/2024	18/12/2023	24/11/2022	31/08/2021	30/10/2020
General meeting	29/05/2025	30/05/2024	14/11/2023	30/05/2022	31/05/2021	25/05/2020
Currency of the financial year	EUR	EUR	EUR	EUR	EUR	EUR
NBB quality label	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls	Satisfying controls

Ratios

Financial ratios

Looking for more information about this company?

Try for 7 days

Filings

Annual accounts filings

19 filings with the NBB

Model	Closing	General meeting	Filed	Language	Document
Micro model	31/12/2024	29/05/2025	14/11/2025	French	PDF
Micro model	31/12/2023	30/05/2024	30/07/2024	French	PDF
Micro model	31/12/2022	14/11/2023	18/12/2023	French	PDF
Abridged model	31/12/2021	30/05/2022	24/11/2022	French	PDF
Micro model	31/12/2020	31/05/2021	31/08/2021	French	PDF
Micro model	31/12/2019	25/05/2020	30/10/2020	French	PDF
Abridged model	31/12/2018	31/05/2019	30/08/2019	French	PDF
Abridged model	31/12/2017	31/05/2018	08/06/2018	French	PDF
Abridged model	31/12/2016	26/05/2017	02/06/2017	French	PDF
Abridged model	31/12/2015	26/05/2016	06/06/2016	French	PDF
Abridged model	31/12/2014	28/05/2015	28/05/2015	French	PDF
Abridged model	31/12/2013	30/05/2014	13/06/2014	French	PDF
Abridged model	31/12/2012	30/05/2013	31/05/2013	French	PDF
Abridged model	31/12/2011	31/05/2012	08/06/2012	French	PDF
Abridged model	31/12/2010	26/05/2011	01/06/2011	French	PDF
Abridged model	31/12/2009	27/05/2010	24/06/2010	French	PDF
Abridged model	31/12/2008	28/05/2009	01/07/2009	French	PDF
Abridged model	31/12/2007	29/05/2008	27/06/2008	French	PDF
Abridged model	31/12/2006	31/05/2007	20/08/2007	French	PDF

Estimate

Indicative valuation

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan

Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Governance

Board of directors

Seen on filing of 31/12/2024 · 1 active · 6 ended

Active mandates

CIEL PHARMA

Administrateur · since 08 novembre 2024 · 0690.987.220

Represented by Ilias Atghaninti

Active

Ended mandates

CIEL PHARMA

Director · since 02 janvier 2019 · 0690.987.220

Represented by ILIAS ATGHANINTI

Ended

MICHELINE DEMARBAIX

Managing director · since 01 juillet 2015

Ended

PAUL MARIE VANDERBORCHT

Managing director · since 01 avril 2001

Ended

CIEL PHARMA

Manager · 0690.987.220

Represented by LLIAS ATGHANINTI

Ended

Shareholders

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette

Belgian Official Gazette publications

Mandates18/11/2024
WIJZIGING RECHTSVORM - MAATSCHAPPELIJKE ZETEL - ONTSLAGEN - BENOEMINGEN
PDF
Mandates18/11/2024
MODIFICATION FORME JURIDIQUE - SIEGE SOCIAL - DEMISSIONS, NOMINATIONS
PDF
Mandates18/01/2019
SIEGE SOCIAL - DEMISSIONS, NOMINATIONS
PDF
Mandates12/12/2016
DEMISSIONS, NOMINATIONS
PDF
Mandates16/07/2015
DEMISSIONS, NOMINATIONS
PDF
Mandates30/06/2004
DEMISSIONS, NOMINATIONS
PDF
Registered office06/05/2004
SIEGE SOCIAL
PDF

Source: Belgian Official Gazette

Competition

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

2024
Annual accounts 202449,1 k €↓
2023
Annual accounts 202367,9 k €↓
2022
Annual accounts 2022158,8 k €↑
2021
Annual accounts 202191,4 k €↑
2020
Annual accounts 202085,0 k €↑
2019
Annual accounts 201921,0 k €↓
2018
Annual accounts 201831,8 k €↓
2017
Annual accounts 201735,2 k €↓
2016
Annual accounts 201643,5 k €↓
2015
Annual accounts 201545,0 k €↑
2014
Annual accounts 201428,4 k €↑
2013
Annual accounts 201322,5 k €↑
2012
Annual accounts 201220,9 k €↓
2011
Annual accounts 201132,4 k €↓
2010
Annual accounts 201049,8 k €↓
2009
Annual accounts 200951,1 k €↑
2008
Annual accounts 200837,2 k €↑
2007
Annual accounts 20077,5 k €↓
2006
Annual accounts 200616,3 k €
03/04/2001
IncorporationPrivate limited company

10/15	1 240 000	1 180 000	1 050 000
70	8 630 000	8 120 000	7 940 000
9904	412 000	388 000	301 000
17/49	2 970 000	3 140 000	3 380 000
9087	24,3	23,1	21,8

DEVAPHAR

Overview

What does DEVAPHAR do?

Trend over 19 financial years

Board of directors

Other companies at this address

Financials

Full financial information

Financial ratios

Annual accounts filings

Valuation

Indicative valuation

Directors & structure

Board of directors

Ownership and network

Publications

Belgian Official Gazette publications

Similar companies

Similar companies

Timeline